Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

shutterstock_274590824

Biogen stock surges following patent victory over Mylan for Tecfidera

February 6, 2020
Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019
Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …

News
biogen_austria_238_29

Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal

November 7, 2019
Sales and Marketing Biogen, Samsung Bioepis, pharma

Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …

News

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019
Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …

News
biogen_austria_238

Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …

News

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …

News
shutterstock_212432119

Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3

July 31, 2019
Research and Development Alkermes, Biogen, multiple sclerosis, pharma

Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …

News

Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy

July 2, 2019
Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy

Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …

News
biogen_austria_238

Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis

May 31, 2019
Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis

New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …

News

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019
Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News
eisa0008_web

Biogen and Eisai discontinue Phase 3 Alzheimer’s trial

March 21, 2019
Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023